QUECTEL-WIRELESS
15.3.2023 09:01:42 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces the launch of its FGH100M Wi-Fi HaLow module, providing long range data transmission, low power consumption, less complexity as well as improved penetration through walls and other obstructions for a wide range of IoT applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005141/en/
Quectel launches Wi-Fi HaLow module to address extensive indoor and outdoor IoT applications (Photo: Business Wire)
Adopting IEEE 802.11ah wireless networking protocol, also known as Wi-Fi HaLow, operating in the license-exempt Sub-1 GHz range, the FGH100M module meets the unique requirements of the Internet of Things (IoT) with its Sub-1 GHz signal coverage, allowing users to control IoT devices in one kilometer radius. It provides ten times the range of traditional Wi-Fi, making it suited for both indoor and outdoor IoT scenarios such as home and industrial automation, smart agriculture, smart city, smart building, warehouse, retail store, campus and more.
“Integrating the game-changing Wi-Fi HaLow technology, our FGH100M module will deliver long range and robust Wi-Fi connections without having to sacrifice simplicity and efficiency,” commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “It is a very powerful complement to our already extensive range of Wi-Fi modules delivering functionality across Wi-Fi 4, Wi-Fi 5, Wi-Fi 6, and Wi-Fi 6E.”
Based on Morse Micro’s MM6108 Wi-Fi HaLow SoC, the FGH100M is compliant with IEEE 802.11ah Wi-Fi standard and operates in 850–950 MHz bands with 1/2/4/8 MHz channel width. It features 21 dBm maximum output power and 32.5 Mbps maximum transmission rate.
The FGH100M Wi-Fi HaLow module enables lower power connectivity than previous Wi-Fi technologies and is able to support coin cell battery devices operating for months or years, which is critical for use cases such as smart sensors and condition monitor. Unlike similar IoT technologies, Wi-Fi HaLow supports native IP and does not require proprietary gateways, controllers, or hubs, which greatly streamlines the installation and reduces operating costs.
With its ultra-compact size of 13.0 mm × 13.0 mm × 2.2 mm, the FGH100M effectively optimizes end-product size and design cost, and fully meets the demands of size-sensitive applications. Additionally, the module provides a wide range of interfaces including UART, SPI, I2C, SDIO 2.0, and PWM.
The FGH100M satisfies the latest Wi-Fi requirements for authentication and encryption including WPA3 and AES for over-the-air (OTA) traffic. It also supports SHA-256, SHA-384, SHA-512 encryption algorithms to better protect transmission data.
Engineering samples of the FGH100M Wi-Fi HaLow module are available now. To learn more about Quectel’s FGH100M, please visit Quectel at Embedded World 2023, Hall 3, Booth 318.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005141/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
